aTyr Pharma Revenue and Competitors
Estimated Revenue & Valuation
- aTyr Pharma's estimated annual revenue is currently $14.4M per year.
- aTyr Pharma's estimated revenue per employee is $155,000
- aTyr Pharma's total funding is $331.8M.
Employee Data
- aTyr Pharma has 93 Employees.
- aTyr Pharma grew their employee count by -7% last year.
aTyr Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Corporate Development | Reveal Email/Phone |
2 | VP, Human Resources | Reveal Email/Phone |
3 | VP Finance | Reveal Email/Phone |
4 | VP External Scientific Alliances and Intellectual Property | Reveal Email/Phone |
5 | General Counsel | Reveal Email/Phone |
6 | VP, Research | Reveal Email/Phone |
7 | VP, Regulatory Affairs | Reveal Email/Phone |
8 | Senior Director | Reveal Email/Phone |
9 | Associate Director | Reveal Email/Phone |
10 | Director | Reveal Email/Phone |
aTyr Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $31800M | 109578 | 4% | $367M | $146B |
What Is aTyr Pharma?
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and clinical development of innovative medicines based on novel immunological pathways. We have concentrated our research and development efforts on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. We have built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. We are focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family, one of the synthetase genes. ATYR1923 is a clinical-stage product candidate, based on the Resokine pathway, which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
keywords:N/A
$331.8M
Total Funding
93
Number of Employees
$14.4M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
aTyr Pharma News
ATYR PHARMA INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and...
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's...
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's...
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registration ...
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initiate in 2022. Se ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.3M | 93 | 11% | N/A |
#2 | $25.1M | 93 | 4% | N/A |
#3 | $25.1M | 93 | 6% | N/A |
#4 | $7.5M | 93 | 22% | N/A |
#5 | $27M | 93 | -3% | N/A |